Gu Jun, Yin Zhao-Fang, Pan Jian-An, Zhang Jun-Feng, Wang Chang Qian
Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine.
Anatol J Cardiol. 2019 Sep;22(3):117-124. doi: 10.14744/AnatolJCardiol.2019.26428.
A higher visit-to-visit variability in low-density lipoprotein cholesterol (LDL-C) is associated with an increased frequency of cardiovascular events. We investigated the association between the visit-to-visit LDL-C variability and all-cause mortality, myocardial infarction (MI), and coronary revascularization in a population with non-obstructive coronary artery disease (CAD).
From this retrospective cohort of individuals who underwent coronary angiography from 2006 to 2010, a total of 2.012 consecutive patients with non-obstructive CAD, who underwent three or more LDL-C determinations during the first 2 years, were identified and followed up for 5 years. The variability in the visit-to-visit LDL-C was measured by standard deviation (SD) and coefficient of variation (CV). The risk of all-cause mortality and composite endpoints, MI, and coronary revascularization were evaluated by a multivariable Cox regression analysis.
During a 5-year follow-up, a total of 99 (4.92%) mortality cases and 154 (7.65%) cases of composite endpoints were observed. The percentage of subjects who experienced mortality or composite endpoints was higher in those with a higher LDL-C-SD or LDL-C-CV level. The association between the LDL-C variability and clinical endpoints was regardless of possible confounding factors.
Among the patients with non-obstructive CAD, a higher visit-to-visit LDL-C variability is associated with increasing all-cause mortality or composite endpoints during the long-term follow-up.
低密度脂蛋白胆固醇(LDL-C)的就诊间变异性增加与心血管事件发生频率升高相关。我们在非阻塞性冠状动脉疾病(CAD)人群中研究了就诊间LDL-C变异性与全因死亡率、心肌梗死(MI)和冠状动脉血运重建之间的关联。
从2006年至2010年接受冠状动脉造影的个体的回顾性队列中,共识别出2012例连续的非阻塞性CAD患者,这些患者在最初2年内进行了三次或更多次LDL-C测定,并随访5年。就诊间LDL-C的变异性通过标准差(SD)和变异系数(CV)来衡量。全因死亡率和复合终点、MI以及冠状动脉血运重建的风险通过多变量Cox回归分析进行评估。
在5年随访期间,共观察到99例(4.92%)死亡病例和154例(7.65%)复合终点病例。LDL-C-SD或LDL-C-CV水平较高的受试者中,经历死亡或复合终点的受试者百分比更高。LDL-C变异性与临床终点之间的关联不受可能的混杂因素影响。
在非阻塞性CAD患者中,较高的就诊间LDL-C变异性与长期随访期间全因死亡率或复合终点增加相关。